Market cap

TG Therapeutics (NASDAQ:TGTX) Adds $271M To Market Cap In Last 7 Days, Though Year-Ago Investors Are Still Down 64%

This month we saw the TG Therapeutics, Inc. (NASDAQ:TGTX) up an impressive 53%. But that doesn’t change the fact that last year’s returns were disappointing. Like a dry lake in a warming world, shareholder value evaporated, with the stock price dropping 64% during that time. It’s not so surprising to see a rebound after a fall like that. You could say the sale was too harsh.

The recent 31% rise could be a positive sign of things to come, so let’s take a lot of look at historical fundamentals.

See our latest review for TG Therapeutics

Given that TG Therapeutics has posted losses over the past twelve months, we think the market is likely more focused on revenue and revenue growth, at least for now. When a business is not making a profit, you generally expect to see good revenue growth. Some companies are ready to postpone profitability to increase revenue faster, but in this case, good revenue growth is expected.

TG Therapeutics increased its revenue by 188% over the past year. That’s way above most other nonprofits. On the other hand, the share price is down 64% over twelve months. Yes, the market can be a fickle mistress. It could mean that the hype is gone from the stock because the end result is for investors. We would certainly consider this a positive if the company is trending towards profitability. If you see this happening, maybe consider adding this stock to your watchlist.

The company’s revenues and profits (over time) are shown in the image below (click to see exact figures).


Take a closer look at the financial health of TG Therapeutics with this free report on its balance sheet.

A different perspective

We regret to report that TG Therapeutics shareholders are down 64% for the year. Unfortunately, this is worse than the general market decline of 10%. However, it could simply be that the stock price was impacted by greater market jitters. It might be worth keeping an eye on the fundamentals, in case there is a good opportunity. Unfortunately, last year’s performance capped a bad run, with shareholders facing a total loss of 5% per year over five years. Generally speaking, long-term stock price weakness can be a bad sign, although contrarian investors may want to seek out the stock in hopes of a turnaround. While it is worth considering the various impacts that market conditions can have on the stock price, there are other, even more important factors. Example: we have identified 4 warning signs for TG Therapeutics you should be aware.

If you like buying stocks alongside management then you might love this free list of companies. (Hint: insiders bought them).

Please note that the market returns quoted in this article reflect the average market-weighted returns of stocks currently trading on US exchanges.

Feedback on this article? Concerned about content? Get in touch with us directly. You can also email the editorial team (at)

This Simply Wall St article is general in nature. We provide commentary based on historical data and analyst forecasts only using unbiased methodology and our articles are not intended to be financial advice. It is not a recommendation to buy or sell stocks and does not take into account your objectives or financial situation. Our goal is to bring you targeted long-term analysis based on fundamental data. Note that our analysis may not take into account the latest announcements from price-sensitive companies or qualitative materials. Simply Wall St has no position in the stocks mentioned.

Join a Paid User Research Session
You will receive a $30 Amazon Gift Card for 1 hour of your time while helping us create better investment tools for individual investors like you. register here